Abstract
Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including the cardiovascular system. Most importantly, in addition to the direct injury from the virus per se, the subsequent cytokine storm, an overproduction of immune cells and their activating compounds, causes devastating damage. To date, emerging anti-SARS-CoV-2 treatments are warranted to control epidemics. Several candidate drugs have been screened and are currently under investigation. These primarily include antiviral regimens and immunomodulatory regimens. However, beyond the anti-SARS-CoV-2 effects, these drugs may also have risks to the cardiovascular system, especially altering cardiac conduction. Herein, we review the cardiovascular risks of potential anti-COVID-19 drugs.
| Original language | English |
|---|---|
| Pages (from-to) | 205-214 |
| Number of pages | 10 |
| Journal | Cardiovascular Drugs and Therapy |
| Volume | 35 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 2021 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Complications
- COVID-19
- Potential cardiotoxicity
- SARS-CoV-2
ASJC Scopus subject areas
- Pharmacology
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
Fingerprint
Dive into the research topics of 'A Double-Edged Sword—Cardiovascular Concerns of Potential Anti-COVID-19 Drugs'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS